Tag Archives: AIMS

June 23, 2020
In The News

The University of Kentucky announced a research collaboration with Atomwise, an industry leader in using artificial intelligence (AI) for small molecule discovery, to explore potential COVID-19 therapies. The project awarded to Dr. Konstantin V. Korotkov is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) awards program, which seeks to democratize access to AI for drug […]

Read Article
September 27, 2019
In The News

Angus Liu of FierceBiotech reports on new research on Miro1 and implications for Parkinson’s disease.

Read Article
September 26, 2019
In The News

Science Daily reports on a recent publication by researchers at Stanford, Mayo Clinic, and Atomwise.

Read Article
May 2, 2019
In The News

Originally published on the YC Blog on April 29, 2019. By Jared Friedman In the last 10 years, the tools for studying biology have become much less expensive and more widely available. This has made it possible for new startups to do serious research right from the start, and it is leading to an explosion […]

Read Article
April 16, 2019
Press Release

Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development   GENEVA, Switzerland and SAN FRANCISCO, USA (April 16, 2019) – Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and the Drugs for Neglected […]

Read Article
April 9, 2019
Press Release

A half dozen University of Connecticut (UConn) researchers are now working to identify potential new drugs to treat a wide range of diseases and conditions through a unique partnership that offers access to cutting-edge artificial intelligence (AI) technology and screening compounds at no cost. The researchers have been using Atomwise’s AI-powered in silico screening technology […]

Read Article